Xenogen Biosciences Announces Target Validation Collaboration Agreement with Schering-Plough

21-Aug-2006

Xenogen Biosciences, acquired on August 9, 2006, by Caliper Life Sciences, Inc. , announced a target validation collaboration with Schering-Plough Corporation, under which Xenogen Biosciences will utilize its proprietary Serial Phenotyping Compression Technology (SPCT) to characterize high value targets resulting from drug discovery research conducted by the Schering-Plough Research Institute.

SPCT evaluates the physiological and behavioral impact of such high value targets by utilizing a battery of more than 85 pharmacologically-validated challenge or bioassays (measuring over 400 individual parameters), and covering most therapeutic areas. The recently signed phenotypic characterization agreement expands on a previous gene targeting agreement aimed at the creation of standard and conditional gene knockouts, both of which contribute to a fuller understanding of the biological effects associated with the deletion of a gene's function. Financial terms of the deal were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

NetScientific appoints Dr François R. Martelet as Chief Executive Officer

Zooming in on protein to prevent kidney stones - Researchers use Nobel prize-winning technology to see vital kidney protein for the first time

ExonHit Announces Termination of Agreement to Acquire RedPath

Designed antiviral proteins inhibit SARS-CoV-2 in the lab - Computer-designed, synthetic miniproteins act as potent, stable antivirals that block coronavirus infection of cultured human cells

Designed antiviral proteins inhibit SARS-CoV-2 in the lab - Computer-designed, synthetic miniproteins act as potent, stable antivirals that block coronavirus infection of cultured human cells

BioStorage Technologies Appoints Thomas J. Newman to Board of Directors

Viral life cycle of malignant catarrhal fever explained

ALTANA Pharma investment runs into triple-digit millions - Extension of the Singen production facility

Topas Therapeutics Raises €22 Million in Series B Financing - Funds to be used to advance innovative pipeline based on Topas Particle Conjugates technology platform

Topas Therapeutics Raises €22 Million in Series B Financing - Funds to be used to advance innovative pipeline based on Topas Particle Conjugates technology platform

AION Diagnostics Announces novel new property to its nanotechnology platform

Caprotec bioanalytics Completes Series B Financing Round of EUR 4 Million

NimbleGen Systems announces partnership with Affymetrix to commercialize custom microarrays - New NimbleExpress(TM) Arrays for Flexible Photolithographic Custom Array Design Compatible with Affymetrix GeneChip® System

Double Trouble: Infamous “Eagle Killer” Bacterium Produces Not One, But Two Toxins - The new findings could help develop new drugs that fight cancer

Double Trouble: Infamous “Eagle Killer” Bacterium Produces Not One, But Two Toxins - The new findings could help develop new drugs that fight cancer